Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate Cancer
2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 3 Linguagem: Inglês
10.1016/s0022-5347(05)64559-4
ISSN1527-3792
AutoresCheol Kwak, Seong Jin Jeong, Moon Soo Park, Eunsik Lee, Sang Eun Lee,
Tópico(s)Cancer, Lipids, and Metabolism
ResumoNo AccessJournal of UrologyCLINICAL UROLOGY: ORIGINAL ARTICLES1 Sep 2002Prognostic Significance of The Nadir Prostate Specific Antigen Level After Hormone Therapy for Prostate Cancer Cheol Kwak, Seong Jin Jeong, Moon Soo Park, Eunsik Lee, and Sang Eun Lee Cheol KwakCheol Kwak More articles by this author , Seong Jin JeongSeong Jin Jeong More articles by this author , Moon Soo ParkMoon Soo Park More articles by this author , Eunsik LeeEunsik Lee More articles by this author , and Sang Eun LeeSang Eun Lee More articles by this author View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64559-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We determine whether the nadir prostate specific antigen (PSA) level after hormone therapy can be used to predict the progression to hormone refractory prostate cancer. Materials and Methods: We reviewed the progressive status and survival of 177 patients with stage C or D prostate cancer who had received hormone therapy at our institution. The overall survival rate, incidence of progression to hormone refractory prostate cancer and interval until progression were analyzed with reference to the nadir PSA level. Multiple regression analysis was used to analyze the predictive factors for progression to hormone refractory prostate cancer, and the relative efficacy of the nadir PSA level in predicting progression was evaluated by receiver operating characteristics analysis. Results: Median followup was 39 months (range 3 to 89) and 85.4% of patients (151) responded to treatment, of whom 77.5% (117) had progression to hormone refractory prostate cancer. Median time until nadir PSA levels were reached after hormone therapy was 8.1 months and median time until hormone refractory prostate cancer was 24.0 months. Nadir PSA levels were less than 0.2 ng./ml. in 31% of respondents, 0.2 to 1.0 ng./ml. in 23%, 1.1 to 10 ng./ml. in 42% and greater than 10 ng./ml. in 5%. These groups had similar clinicopathological characteristics. Nadir PSA levels correlated significantly with pretreatment PSA levels, Gleason scores and progression to hormone refractory prostate cancer (p = 0.01, p <0.01 and p <0.001, respectively), and inversely correlated with the interval to the establishment of hormone refractory prostate cancer (r = −0.465, p <0.05). By univariate analysis bone metastasis, nadir PSA, PSA at 6 months after treatment and pretreatment PSA were significantly associated with progression to hormone refractory prostate cancer. Only the nadir PSA was calculated to be an independent factor by multivariate analysis. Receiver operating characteristics analysis indicated that nadir PSA predicted progression to hormone refractory prostate cancer after 2 years with an accuracy of 86.2%. With the lower limit of the nadir PSA level set to 1.1 ng./ml., sensitivity was 80.3% and specificity was 83.8%, and these levels were deemed the most appropriate. Furthermore, nadir PSA after hormone therapy was an independent prognosticator for survival, as were initial levels of hemoglobin and alkaline phosphatase. Conclusions: The nadir PSA level after hormone therapy may be the most accurate factor predicting the progression to hormone refractory prostate cancer and is an independent prognostic factor for survival. Furthermore, a lower limit for the nadir PSA level of 1.1 ng./ml. gives optimal sensitivity and specificity. References 1 : Goserelin acetate flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853).EORTC GU Group EORTC Data Center. Urology1993; 42: 119. Google Scholar 2 : Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol1992; 21: 2. Google Scholar 3 : Prostate specific antigen prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate. J Urol1991; 146: 1064. Abstract, Google Scholar 4 : Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol1991; 146: 358. Link, Google Scholar 5 : Hormone therapy in prostate cancer. Am J Med1956; 21: 697. Google Scholar 6 : Ethnic differences in the age-related distribution of serum prostate-specific antigen values: a study in a healthy Korean male population. Urology2000; 56: 1007. Google Scholar 7 : Criteria for evaluating patient responses to treatment modalities for prostatic cancer. Urol Clin North Am1984; 11: 337. Google Scholar 8 : Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex). Br J Urol1986; 58: 676. Google Scholar 9 : Prostatic specific antigen the prediction of prognosis in metastatic prostatic cancer. Cancer1990; 66: 1025. Google Scholar 10 : Prostatic specific antigen prostatic acid phosphatase in the monitoring staging of patients with prostatic cancer. J Urol1987; 138: 1181. Abstract, Google Scholar 11 : The usefulness of prostate-specific antigen prostatic acid phosphatase in clinical practice. Am J Clin Oncol1988; 11: S53. Google Scholar 12 : Analysis of prognostic factors in patients with metastatic prostate cancer. Kor J Urol2000; 41: 205. Google Scholar 13 : The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol1992; 147: 956. Link, Google Scholar 14 : Nadir P-SA as a progression to androgen-independent prostate cancer. Urology2002; 59: 73. Google Scholar 15 : PSA correlation with response survival in advanced carcinoma of the prostate. J Urol1993; 149: 430A. Google Scholar From the Department of Urology, Seoul National University College of Medicine and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByAydemir H and Kumsar Ş (2018) Re: Cytoreductive Radical Prostatectomy in Patients with Prostate Cancer and Low Volume Skeletal Metastases: Results of a Feasibility and Case-Control StudyJournal of Urology, VOL. 194, NO. 3, (853-855), Online publication date: 1-Sep-2015.Robinson D, Sandblom G, Johansson R, Garmo H, Stattin P, Mommsen S and Varenhorst E (2018) Prediction of Survival of Metastatic Prostate Cancer Based on Early Serial Measurements of Prostate Specific Antigen and Alkaline PhosphataseJournal of Urology, VOL. 179, NO. 1, (117-123), Online publication date: 1-Jan-2008.PEYROMAURE M, DEBRÉ B, MAO K, ZHANG G, WANG Y, SUN Z, XU D, JIANG J and SUN Y (2018) MANAGEMENT OF PROSTATE CANCER IN CHINA: A MULTICENTER REPORT OF 6 INSTITUTIONSJournal of Urology, VOL. 174, NO. 5, (1794-1797), Online publication date: 1-Nov-2005.SHULMAN M and BENAIM E (2018) THE NATURAL HISTORY OF ANDROGEN INDEPENDENT PROSTATE CANCERJournal of Urology, VOL. 172, NO. 1, (141-145), Online publication date: 1-Jul-2004. Volume 168Issue 3September 2002Page: 995-1000 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsprostatic neoplasmshormones, prostate-specific antigenMetricsAuthor Information Cheol Kwak More articles by this author Seong Jin Jeong More articles by this author Moon Soo Park More articles by this author Eunsik Lee More articles by this author Sang Eun Lee More articles by this author Expand All Advertisement PDF DownloadLoading ...
Referência(s)